Rising rates of paracoccidioidomycosis-related hospitalizations and in-hospital deaths, Rio de Janeiro, Brazil (2010-2019)

IF 2.7 3区医学 Q3 INFECTIOUS DISEASES

Medical mycology Pub Date : 2024-04-30 DOI:10.1093/mmy/myae048

Eduardo Mastrangelo Marinho Falcão, Priscila Marques de Macedo, Ziadir Francisco Coutinho, Francisco Inacio Bastos, Antonio Carlos Francesconi do Valle

引用次数: 0

Abstract

The epidemiological dynamics of paracoccidioidomycosis (PCM) has been changing over the years. We analyzed secondary public data from the Hospital Information System of the Brazilian Unified Health System (SIH/SUS), focusing on PCM-related hospitalizations and in-hospital deaths. In the period between 2010 and 2019, 396 hospitalizations and 30 deaths were related to PCM among 7 073 334 hospitalizations registered in Rio de Janeiro. We highlight the rising rates, reflecting the increase in the number of acute forms previously reported. Urgent public health policies are essential to prevent poor outcomes related to this neglected mycosis.

查看原文本刊更多论文

巴西里约热内卢与副球孢子菌病相关的住院率和院内死亡率上升（2010-2019年）

副球孢子菌病 (PCM) 的流行病学动态多年来一直在发生变化。我们分析了巴西统一卫生系统医院信息系统（SIH/SUS）中的二级公共数据，重点关注与 PCM 相关的住院和院内死亡病例。2010 年至 2019 年期间，在里约热内卢登记的 7 073 334 例住院患者中，有 396 例住院和 30 例死亡与肺结核有关。我们强调了这一比例的上升，这反映了之前报告的急性病例数量的增加。为防止这种被忽视的真菌病造成不良后果，必须采取紧急公共卫生政策。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Medical mycology 医学-兽医学

CiteScore

5.70

自引率

3.40%

发文量

632

审稿时长

12 months

期刊介绍： Medical Mycology is a peer-reviewed international journal that focuses on original and innovative basic and applied studies, as well as learned reviews on all aspects of medical, veterinary and environmental mycology as related to disease. The objective is to present the highest quality scientific reports from throughout the world on divergent topics. These topics include the phylogeny of fungal pathogens, epidemiology and public health mycology themes, new approaches in the diagnosis and treatment of mycoses including clinical trials and guidelines, pharmacology and antifungal susceptibilities, changes in taxonomy, description of new or unusual fungi associated with human or animal disease, immunology of fungal infections, vaccinology for prevention of fungal infections, pathogenesis and virulence, and the molecular biology of pathogenic fungi in vitro and in vivo, including genomics, transcriptomics, metabolomics, and proteomics. Case reports are no longer accepted. In addition, studies of natural products showing inhibitory activity against pathogenic fungi are not accepted without chemical characterization and identification of the compounds responsible for the inhibitory activity.